Press
Releases

November 13, 2024 Jade Biosciences to Participate in Upcoming Investor Conferences October 31, 2024 Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement October 24, 2024 Jade Biosciences Appoints Tom Frohlich as Chief Executive Officer and Hetal Kocinsky as Chief Medical Officer; Forms Board of Directors and Expands Financing to $95 Million August 1, 2024 Jade Biosciences Launches with $80 Million to Develop Transformative Therapies for Autoimmune Diseases